Thursday, October 25, 2007
Bloomberg.com: Worldwide
Bloomberg.com: Worldwide: "Oct. 25 (Bloomberg) -- It's not enough for Eli Lilly & Co.'s anti-clotting drug prasugrel to be approved by U.S. regulators. Unless the medicine works better than Bristol-Myers Squibb Co. and Sanofi-Aventis SA's Plavix, it's a failure."
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment